Hospital
Norcal Healthconnect LLC
Norcal Healthconnect LLC was paid $12.20M by Medicaid between Jan 2018 and Nov 2024, across 163 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 15% of everything it billed.
33Billing provider infoNORCAL HEALTHCONNECT LLC
PETALUMA, CA 94954
PETALUMA, CA 94954
33aNPI1235162645assigned 07/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.20M
24GClaims283,038
24DCodes billed163
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#162 of 410
Median peer was paid$6.90M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,265 | $2.00M | |
| 2019 | 38,059 | $1.64M | |
| 2020 | 30,378 | $1.31M | |
| 2021 | 37,572 | $1.58M | |
| 2022 | 45,937 | $1.84M | |
| 2023 | 46,683 | $1.93M | |
| 2024incomplete | 45,144 | $1.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 15% | 22,177 | 19,296 | $1.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 26,184 | 22,992 | $1.51M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,529 | 2,431 | $827K |
| 93976 | 5.9% | 2,526 | 2,505 | $724K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 5.1% | 4,220 | 4,156 | $618K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 5,437 | 4,975 | $449K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 2,127 | 2,056 | $409K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.8% | 2,384 | 2,199 | $337K |
| J3490 | Unclassified drugs | 2.2% | 30,619 | 15,429 | $268K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 6,528 | 5,954 | $251K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 4,873 | 4,274 | $245K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.8% | 2,287 | 2,220 | $220K |
151 more codes
| 99201 | 1.6% | 1,355 | $199K | |
| 76830 | Ultrasound, transvaginal | 1.6% | 2,026 | $196K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.5% | 1,034 | $189K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.4% | 3,926 | $170K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.4% | 1,941 | $166K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,070 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,462 | $158K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 818 | $157K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.3% | 380 | $157K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,875 | $153K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 2,775 | $143K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,260 | $114K |
| 80053 | Comprehensive metabolic panel | <1% | 12,889 | $113K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,768 | $104K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,044 | $104K |
| 97139 | <1% | 2,001 | $102K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 863 | $96K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,095 | $93K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,415 | $92K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 259 | $91K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,483 | $89K |
| 73630 | <1% | 1,988 | $71K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,700 | $68K |
| 87631 | <1% | 1,296 | $65K | |
| 73610 | <1% | 1,361 | $55K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,292 | $54K |
| 73030 | <1% | 1,396 | $53K | |
| 72100 | <1% | 1,153 | $48K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 551 | $47K |
| 83880 | <1% | 1,788 | $46K | |
| 83605 | <1% | 5,170 | $45K | |
| 84484 | <1% | 5,210 | $44K | |
| 76641 | <1% | 375 | $43K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 648 | $42K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 368 | $42K |
| 73130 | <1% | 1,048 | $40K | |
| 0450 | Emergency room services | <1% | 269 | $38K |
| 76770 | <1% | 349 | $37K | |
| 73562 | <1% | 1,024 | $36K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,244 | $35K |
| Z7502 | <1% | 905 | $35K | |
| 83690 | <1% | 6,101 | $33K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 115 | $30K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 993 | $30K |
| 73564 | <1% | 658 | $27K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,225 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 486 | $25K |
| 73110 | <1% | 584 | $23K | |
| 76999 | <1% | 183 | $22K | |
| 87040 | <1% | 2,107 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,545 | $19K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 764 | $19K |
| 76536 | <1% | 236 | $19K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 748 | $19K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,809 | $18K |
| 77066 | Tomosynthesis, mammo | <1% | 105 | $18K |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 95 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 56 | $16K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,274 | $16K |
| 81001 | <1% | 5,095 | $16K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,231 | $15K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,331 | $15K |
| 74018 | <1% | 576 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,094 | $14K |
| 85610 | <1% | 4,237 | $14K | |
| 85379 | <1% | 1,562 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,498 | $12K |
| 76642 | <1% | 158 | $12K | |
| 93971 | <1% | 93 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,775 | $12K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,577 | $11K |
| 84145 | <1% | 591 | $11K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 24 | $9K |
| Z7610 | <1% | 736 | $9K | |
| 83735 | <1% | 1,736 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 641 | $9K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 253 | $8K |
| 81003 | <1% | 3,866 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 908 | $8K |
| 72050 | <1% | 119 | $7K | |
| 72110 | <1% | 108 | $7K | |
| 90715 | <1% | 153 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 941 | $6K |
| 99070 | <1% | 388 | $6K | |
| 81025 | <1% | 2,009 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 94 | $6K |
| 80306 | <1% | 378 | $6K | |
| 73221 | <1% | 14 | $6K | |
| 77065 | Tomosynthesis, mammo | <1% | 30 | $5K |
| 87400 | <1% | 538 | $5K | |
| 71271 | <1% | 36 | $5K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 13 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 68 | $5K |
| 72141 | <1% | 12 | $5K | |
| 73502 | <1% | 96 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $5K |
| 87077 | <1% | 627 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 25 | $4K |
| 80076 | <1% | 686 | $4K | |
| Z9725 | <1% | 82 | $4K | |
| 72040 | <1% | 87 | $3K | |
| 85730 | <1% | 665 | $3K | |
| 71250 | <1% | 14 | $3K | |
| 87081 | <1% | 547 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 411 | $3K |
| 97750 | <1% | 27 | $2K | |
| 73140 | <1% | 81 | $2K | |
| 87186 | <1% | 258 | $2K | |
| 82077 | <1% | 118 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 266 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 192 | $2K |
| 80047 | <1% | 141 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 83 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $1K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $1K |
| 82962 | <1% | 357 | $997.27 | |
| 85027 | <1% | 211 | $966.54 | |
| 86901 | <1% | 422 | $907.24 | |
| 82550 | <1% | 194 | $870.04 | |
| 86900 | <1% | 404 | $839.48 | |
| 73560 | <1% | 28 | $819.00 | |
| 82805 | <1% | 40 | $748.56 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 29 | $719.52 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 29 | $716.88 |
| 72070 | <1% | 12 | $533.64 | |
| 82248 | <1% | 144 | $517.80 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 36 | $501.38 |
| 80143 | <1% | 27 | $448.69 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 58 | $432.80 |
| 86140 | <1% | 62 | $419.94 | |
| 87807 | <1% | 61 | $418.46 | |
| 86850 | <1% | 143 | $379.96 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 52 | $372.76 |
| 12001 | <1% | 12 | $340.80 | |
| 80179 | <1% | 27 | $336.17 | |
| 87420 | <1% | 138 | $322.92 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 28 | $264.14 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 48 | $225.16 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 15 | $192.90 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 12 | $169.14 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 15 | $166.08 |
| 29125 | <1% | 14 | $165.62 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 30 | $135.45 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 12 | $118.75 |
| 85651 | <1% | 52 | $91.20 | |
| 82553 | <1% | 12 | $88.68 | |
| 87070 | <1% | 12 | $66.12 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $57.98 |
| 84100 | <1% | 14 | $46.84 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 83 | $1.78 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 14 | $0.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.